The discovery of high prevalences of antibiotic resistance in some pathogens, in some parts of the world, has provoked fears of a widespread loss of drug e¤cacy. Here, we use a mathematical model to investigate the evolution of resistance to four major anti-tuberculosis drugs (isoniazid, rifampicin, ethambutol and streptomycin) in 47 sites around the world. The model provides a new method of estimating the relative risk of treatment failure for patients carrying drug-resistant strains and the proportion of patients who develop resistance after failing treatment. Using estimates of these two quantities together with other published data, we reconstructed the epidemic spread of isoniazid resistance over the past 50 years. The predicted median prevalence of resistance among new cases today was 7.0% (range 0.9^64.3%), close to the 6.3% (range 0^28.1%) observed. Predicted and observed prevalences of resistance to isoniazid plus rifampicin (multidrug-resistant or MDR-TB) after 30 years of combined drug use were also similar, 0.9% (0.1^5.9%) and 1.0% (range 0^14.1%), respectively. With current data, and under prevailing treatment practices, it appears that MDR-TB will remain a localized problem, rather than becoming a global obstacle to tuberculosis control. To substantiate this result, further measurements are needed of the relative ¢tness of drug-resistant strains.
INTRODUCTION
Antibiotic resistance threatens to compromise the treatment of 16 million prevalent tuberculosis (TB) cases around the world and to hinder e¡orts to cut the annual death toll of two million people (Pablos- Mendez et al. 1998; Espinal et al. 2000a,b) . Expressions of concern and calls for action are running some way ahead of a su¤cient understanding of why resistance is spreading. Observations have been made in a few countries, for a few years, on resistance trends, but it remains unclear under what circumstances the prevalence of drug resistance will continue to increase, and to what levels. Our goal in this paper is to de¢ne these circumstances more precisely, and hence to specify more accurately epidemiological criteria for the control of drug-resistant TB. The spotlight is on TB, but we make use of fundamental evolutionary principles, taking an approach that could be applied to a wide range of infectious agents.
We ¢rst make use of new data from 47 sites around the world (Espinal et al. 2000b ) to evaluate two quantities that in£uence the rate of spread of resistance. They are (i) the relative risk of treatment failure for patients carrying drug-resistant strains as compared with drugsusceptible strains; and (ii) the proportion of patients who develop resistance on failing treatment (the`ampli¢er e¡ect'; Farmer & Kim 1998) . Mathematical modelling shows how these two quantities can be derived from the relationship between measured resistance prevalences in new and previously treated TB cases. The second part of the paper examines the epidemiological signi¢cance of these parameter estimates by combining them in a full transmission model, and by comparing observed and expected prevalences of drug resistance around the world.
Our analysis leads to the proposition that the global average prevalence of anti-TB drug resistance will remain low. This prediction from modelling, based on new data, is more sanguine than previous analyses (Blower et al. 1996; Dye & Williams 2000) , and consistent with observed resistance prevalences around the world. It suggests that drug-resistant Mycobacterium tuberculosis (MTB), and particularly multidrug-resistant strains of MTB, are not in the process of replacing drug-susceptible strains worldwide.
METHODS

(a) Treatment failure and the selection of drug-resistant strains
During an outbreak of drug-resistant TB, we ¢rst see resistance in patients who have failed treatment. Strains of drugresistant bacilli, which have arisen by mutation, have an advantage over drug-susceptible strains when the dosage of one or a combination of drugs is too low, i.e. when the treatment regimen is less than recommended (Crofton et al. 1997) . Patients may receive inadequate regimens because p rescriptions are wrong, because they default from treatment or because they take drugs erratically. Pulmonary TB patients carrying resistant bacilli, and with open cavities, can transmit these bacilli to other people who have never before had the disease.
Surveys of antibiotic resistance typically p rovide data describing the resistance p revalences among new and previously treated cases (Espinal et al. 2000b) . Previously treated resistant cases ( P ' , where the prime denotes`drug resistant') come from four sources: new resistant cases (I ') who have failed treatment; previously treated resistant cases (P ') who have failed treatment again; new drug-susceptible cases ( I ) who have both failed treatment and acquired, through mutation and selection, resistant strains of bacilli; and previously treated drug-susceptible cases (P) who have again failed treatment and become resistant. Thus, the incidence rate of P ' (written as ¢P ') after a cycle of treatment, failure and re-treatment (i.e. over the interval t to t + 1) is
where¯is the prop ortion of cases detected and hence treated p er unit time, µ is the proportion of drug-susceptible cases who are cured, µ 0 is the p rop ortion of drug-resistant cases cured and » is the prop ortion of patients who become resistant to any given drug on failing treatment (the prop ortion who acquire resistance). The incidence of previously treated drug-susceptible cases is
and the ratio of the two incidence rates, ¢P '/¢PˆP r , is
P r can be measured from the ratio of incident drug-resistant to incident drug-susceptible cases, who have been previously treated. Similarly, (I 0 t ‡ P 0 t )=(I t ‡ P t ) (let this be A r ) can be measured from the ratio of all incident-resistant cases to all incident-susceptible cases, if the ratio of prevalences is the same as the ratio of incidences. This assumes that resistant and susceptible cases are detected at the same rate per capita, and hence exist for the same length of time. Finally, the ratio (1 ¡ µ 0 )=(1 ¡ µ) (let this be ¿) can be interpreted as the relative risk of treatment failure among drug-resistant as compared with drug-susceptible cases. Equation (3) shows that parameters ¿ and » can be estimated from a linear regression of P r on A r :
where the intercept aˆ»=(1 ¡ ») and the gradient bˆ¿=(1 ¡ »), so that »ˆa=(1 ‡ a) and ¿ˆb=(1 ‡ a). In this formulation, the regression variables are not completely indep endentöboth include the number of previously treated casesöand will therefore be correlated. However, we are not concerned here with testing statistically for b 4 0; rather, we want to be sure that b and a lead to unbiased estimates of ¿ and ». We performed a set of Monte Carlo simulations to con¢rm that b and a are indeed unbiased estimators. Our source of data for estimating ¿ and » is Espinal et al. (2000b) , who p rovide matching data on P r and A r from 47 countries, or p arts of countries, around the world.
(b) Observed and expected prevalence of drug resistance in populations
Equations (1) and (2) full cycle, modi¢ed from Dye & Williams (2000) , is in Appendix A. Parameter estimates for the model, with ranges and distributions, are as p reviously described, except for the following new information (see also table A1). Two recent studies of the molecular epidemiology of TB clusters (two or more cases with identical restriction fragment length p olymorphism patterns, presumed to be related by transmission) p rovide estimates of the relative ¢tness (the ratio of basic case reproduction numbers) of drug-resistant as compared with drug-susceptible TB. First, D. van Soolingen and collaborators (personal communication) found that MTB strains carrying the AA315 mutation, which is associated with isoniazid resistance, did not generate signi¢cantly fewer clusters of secondary cases than isoniazid-susceptible strains (relative risk, RRˆ0.8, 95% CI 0.6^1.2). They previously found that isoniazid-resistant strains did generate fewer clusters of cases (RRˆ0.7, 95% CI 0.5^0.9; Van Soolingen et al. 1999) , though results of the two studies are not signi¢cantly di¡erent. With this uncertainty, we allow the relative ¢tness of izoniazid-resistant strains to vary uniformly between 0.5 and 1.0. In the second study, GarciaGarcia et al. (2000) reported that cases resistant to both isoniazid and rifampicin (MDR-TB) generated only 16% (95% CI 4^60%) as many clusters of cases as drug-susceptible strains. Based on this result, we allow the relative ¢tness of MDR strains to vary uniformly between 0.04 and 0.6, where the uniform distribution allows maximal uncertainty from minimal data. These estimates of relative ¢tness are based on the relative numbers of clusters of cases generated by di¡erent strains. They are not directly dep endent on the absolute number of clusters observed in these studies, which is sensitive to the completeness of sampling schedules (Glynn et al. 1999) .
The relative ¢tness of drug-resistant strains must be calculated over the entire life cycle of MTB, including transmissibility, the duration of infectiousness and human susceptibility to disease. Clustering studies do sample over a full generation of MTB. For mathematical modelling, we adjusted the relative ¢tness by changing the transmission or contact rate, c, with which the basic case reproduction number, R 0 , varies in direct prop ortion (see App endix A).
To reconstruct epidemics of drug resistance over the past few decades, we ¢rst used equations (A1)^(A8) (with time-step 0.1 year) to establish a modelpopulation with stable, drug-susceptible disease only. Case detection (¯) and cure rates (µ) were set at 50% p er year and 70%, resp ectively, generating an equilibrium prevalence of infection of ca. 30%, and a steady incidence rate of new infectious cases of ca. 50 p er 100 000 p er year. These rates are typical of the many highly endemic countries (Dye et al. 1999) . Cases of either isoniazid resistance or MDR-TB were then introduced to this p opulation by allowing resistance to arise among treatment failures (» 4 0, estimated as above). The epidemic of isoniazid resistance has been underway for 50 years (since the drug was ¢rst introduced) and the ep idemic of MDR-TB resistance for 30 years (since rifampicin was introduced). We compared the predicted prevalences of isoniazid resistance and MDR-TB after 50 and 30 years with the prevalences observed by Espinal et al. (2000b) . Uncertainty and sensitivity analyses were carried out by Monte Carlo simulation using Palisade @Risk (Dye & Williams 2000) and parameter values with ranges in table A1.
RESULTS
(a) Treatment failure and the selection of drug-resistant strains Regressions of P r on A r for isoniazid, rifampicin, ethambutol and streptomycin, and for MDR, are shown in ¢gure 1. The regression statistics and the resulting estimates of parameters ¿ and » are in table 1. Figure 1 and table 1 together illustrate four main results. First, the range of ratios of resistant to susceptible cases is greatest for isoniazid and streptomycin. These are the drugs that have been used longestöstreptomycin since the 1940s and isoniazid since the 1950s. Ethambutol (1960s) was introduced before rifampicin (1970s), but has been used less intensively. Second, estimates of ¿ are greater than one, indicating, as expected, that treatment failure has been more frequent for drug-resistant as compared with drug-sensitive strains. Third, the largest estimate of ¿ is for rifampicin (table 1). Rifampicin resistance is strongly associated with MDR, for which ¿ is also relatively high (2.49). Fourth, all estimates of » are positive, and all are signi¢cantly greater than zero (t5 2.8, p 5 0.01), with the exception of that for streptomycin. On average, 7.3% of treatment failures develops resistance (»ˆ0.073). The other estimates of » imply that isoniazid resistance is more easily selected than resistance to other drugs when treatment fails, but the di¡erences between drugs are not statistically signi¢cant.
(b) Observed and expected prevalence of drug resistance in populations
We can explore the epidemiological signi¢cance of estimates for ¿ and » by putting them in the full model (see Appendix A), and then solving to forecast the spread of resistance from the point at which drugs were introduced. A complete set of parameter estimates is available for isoniazid-resistant and MDR strains.
Before making comparisons of observed and expected prevalences of drug resistance (the fraction of incident cases that is drug resistant), we ¢rst make some general observations on the relationship between prevalences and numbers of resistant cases. When a new drug is used to treat TB patients, both the number of resistant cases and the prevalence of resistance will at ¢rst increase, provided some patients fail treatment (¢gure 2a^d ). What happens thereafter depends on the absolute and relative magnitudes of the basic case reproduction numbers of drugsusceptible (R 0S ) and drug-resistant disease (R 0R ). Consider a new drug that is used poorly so that case detection and cure rates remain unaltered after its introduction. If R 0S 41 and R 0S 4 R 0R , the incidence and prevalence of resistance increase to a steady state in which fewer than 100% of new cases are resistant (¢gure 2a). If resistant strains have the biggest reproduction number (R 0R 4 R 0S 41), drug-resistant disease will eventually replace drug-susceptible disease altogether (¢gure 2b ).
Expectations for the performance of a new drug would, however, be much higher. If the case detection and cure rates of drug-susceptible disease rise so that R 0S falls below 1, the incidence of drug-susceptible disease will decline towards elimination. If R 0R 51 too, because, for example, the resistant strain has low transmissibility, the number of resistant cases will ¢rst rise and then fall (¢gure 2c). But if the resistant strain is highly transmissible (R 0R 41 while R 0S 51), its incidence will increase as drug-susceptible disease proceeds to extinction (¢gure 2d ). With these various combinations of reproduction numbers the prevalence of drug resistance always increases through time, but the numbers of resistant cases may go up and/or down. The prevalence of resistance will only decline if a control programme succeeds in cutting the incidence of drug-resistant cases more than the incidence of drug susceptibles. This can be done by intervening during an epidemic to cure a higher proportion of drug-resistant cases, thereby preventing transmission (¢gure 2e). It can also be done by curing a higher proportion of drugsusceptible cases (preventing the development of resistance), but only if R 0R is not too large (¢gure 2 f ).
The model forecasts a median prevalence of isoniazid resistance of 7.0% (range 0.9^64.3%) after 50 years of drug use. This is about the same as the observed median of 6.3% (0^28.1%) reported from the 47 sites described by Espinal et al. (2000b) (¢gure 3a,c) . The forecast for MDR-TB is 0.9% (0.1^5.9%) after 30 years of drug use, close to the observed median of 1.0% (0^14.1%) (¢gure 3b,d ). Most strikingly, the forecasts in ¢gure 3 suggest that, on average, the prevalences of isoniazid resistance and MDR have already been close to saturation for decades and are likely to remain below 5%. The model is less likely, a priori, to represent accurately variation around the median; nonetheless, the frequency distributions of observations were similar for model and data (¢gure 3c,d ).
However, in some countries (and parts of countries) the prevalence of MDR is much higher than 5%, e.g. 11% in Henan Province, China, 14% in Estonia, 9% in Latvia and 9% in Ivanovo Oblast, Russia (Espinal et al. 2000b) . These rates exceed the upper bounds of model forecasts in ¢gure 3 and require explanation.
There are three main reasons why MDR rates can be high. A sensitivity analysis of the results in ¢gure 3 shows that rates of isoniazid resistance after 50 years, and of MDR after 30 years, are most in£uenced by uncertainty in the relative transmission rate of drug-resistant strains, c'/c, the proportion of drug-susceptible cases cured, µ, and the proportion acquiring resistance, » (table 2). The relative transmission or contact rate is the most important of these parameters because of its in£uence on the basic case reproduction number, R 0 . If c'/c is about 0.5, a high estimate according to Garcia-Garcia et al. (2000) , the MDR rate saturates at under 5% (¢gure 4a). But if c'/c is close to 1, MDR is still spreading quickly after 30 years, and would eventually replace all other strains of M. tuberculosis. The e¡ect of increasing » is quite di¡erent: the MDR rate saturates below 15%, even with » as high as 0.9 (¢gure 4b). A high proportion acquiring resistance has the same e¡ect as a low cure rate of drug-susceptible cases; in ¢gure 4c, the MDR rate reaches a maximum of less than 15%, even with µ as low as 0.6.
DISCUSSION
Our main result, based on the newest data and prevailing treatment practices, is that TB resistant to isoniazid, or to isoniazid plus rifampicin (MDR-TB), is likely to remain at low levels in most parts of the world. This is consistent with the ¢ndings of the most recent global review, in which signi¢cant upward trends in isoniazid resistance were reported in only four out of 25 countries studied, and a rise in the prevalence of MDR in only one country, Estonia (Espinal et al. 2000b) . The predicted, stable coexistence between drug-resistant and drug-susceptible disease is also consistent with previous theoretical work (Castillo-Chavez & Feng 1997) . Our forecasts suggest that drug-resistant TB, and particularly multidrug-resistant strains of TB, are not in the process of replacing drug-susceptible strains globally. Although TB cases are continuously emigrating from countries where the prevalence of drug resistance is high (and we have not investigated the consequences of such movement), it seems unlikely that MDR-TB, if left untreated, will`a¡ect tens of millions worldwide' (Heymann et al. 1999) .
However, we need more information to be con¢dent about this prediction. It is vital to understand why the prevalence of drug resistance has already reached exceptionally high levels in some countries, such as the Baltic States and parts of India, Russia and China. In the present analysis, the most important unknown is the relative ¢tness (here represented by relative transmissibility or contact rate, c'/c) of resistant as compared with susceptible strains. If the prevalence of resistance and the number of resistant cases are increasing because resistant strains are almost as transmissible as susceptible strains (c'ºc), then the task is to interrupt a sustainable transmission cycle. In the language of deterministic epidemic theory, the goal is to reduce the basic case reproduction number of drug-resistant disease below 1 (R 0R 51). Our previous analysis of the drug-resistance problem (Dye & Williams 2000) allowed for the possibility that MDR strains do indeed have high relative ¢tness (so that R 0R 41). Erring towards caution, we concluded that controlling the epidemic would require higher cure rates for resistant cases. The method of control for MDR-TB would be to draw on the small armoury of expensive and relatively toxic second-line drugs.
This new analysis, based on new data, o¡ers a more benign view of the epidemic of antibiotic resistance. In particular, if MDR strains have low relative ¢tness (Garcia-Garcia et al. 2000) we must look for other explanations for high resistance prevalences. The main contenders are that the cure rate of drug-susceptible disease (and hence, probably, of drug-resistant disease) has been low (small µ), or that treatment failure readily selects for resistance (large »). In either case, the principal remedy will be to use ¢rst-line drugs to their full potential. Short-course chemotherapy can cure over 85% of pan-susceptible cases and up to 80% of cases resistant to either isoniazid or rifampicin (Espinal et al. 2000a) . A high cure rate for drug-susceptible cases, coupled with a high rate of case detection, will force down the incidence of drug-resistant cases and, provided R 0R is not large, the prevalence of drug resistance among all cases. Under these circumstances, second-line drugs would be needed as a back-up to cure individual drug-resistant cases, but not to contain the epidemic.
We have proposed in this paper a new method for estimating both », the fraction of patients who acquire drug resistance after failing treatment, and ¿, the relative risk of treatment failure in patients with drugresistant disease. The method is indirect, but has some advantages over cohort studies: information is already freely available for many patients in many parts of the world; and the estimates re£ect the outcome of common treatment practices rather than the results of tightly controlled trials. Moreover, simulation studies suggest that the method gives unbiased estimates of » and ¿. One disadvantage is that parameter estimates are averages, which conceal important variation, for example, between countries.
There are presently few direct estimates of the relative treatment failure (¿) and the proportion of cases acquiring resistance (») that can be compared with the indirect estimates presented here. Espinal et al. (2000b) reported average relative failure rates for isoniazid, rifampicin and MDR-TB of 1.4, 1.6 and 2.1, as compared with outcomes for drug-susceptible cases. These are similar to our own indirect estimates of 1.1, 2.1 and 2.2. By contrast, direct estimates of the proportion of patients becoming resistant do not always correspond with our indirect estimates. L. Rigouts and colleagues (personal communication) found in a small study that ten out of 12 TB patients carrying isoniazid-resistant strains also acquired rifampicin resistance after failing treatment, thereby becoming multidrug resistant. This gives »ˆ0.83, which is more than ten times higher than our estimate of »ˆ0.070. A study by the Indian Council for Medical Research (personal communication) also obtained a high value of »ˆ32/60ˆ0.53 for the proportion of cases that fail treatment and acquire MDR-TB (rifampicin resistance adding to isoniazid resistance). But estimates of » for isoniazid and rifampicin resistance in patients carrying fully susceptible strains were only 5/25ˆ0.2 and 1/25ˆ0.04, respectively, which are close to our own estimates of 0.13 and 0.08. The rate of development of monoresistance may be relatively low because patients are more likely to fail for reasons other than drug resistance. Discrepancies in the comparisons for MDR remain to be explained. The di¡erences could be resolved by testing the assumptions of our model (e.g. that the detection and treatment rates of drug-susceptible and drug-resistant cases are the same) and by making further direct observations on the proportion of patients who acquire resistance having failed treatment.
Last, our calculations warn against de¢ning the course of drug-resistance epidemics, or progress in their control, solely in terms of prevalence (i.e. the fraction of cases that is resistant, often called a`rate'). It has been noted that the prevalence of resistance can remain high, even in countries that have achieved high rates of case detection and cure (Horsburgh 2000) . But we have shown here how, in principle, the prevalence of resistance can go up while, more importantly, the number of resistant cases is going down.
In conclusion, the crux of the drug-resistance problem is to determine whether drug-resistant strains, including MDR-TB, can persist in self-sustaining transmission cycles. If they cannot, as suggested by this analysis, containment will require high cure rates for susceptible cases only. If they can, containment will require high cure rates for resistant cases too. Molecular epidemiological studies of relative ¢tness (Van Soolingen et al. 1999; Garcia-Garcia et al. 2000) are one approach to ¢nding out. Another is to closely observe control programmes that have adopted best practices in standard short-course chemotherapy, without introducing second-line drugs to treat MDR-TB cases (as recommended by Crofton et al. 1997) , to see if the incidence of drug-resistant as well as drug-susceptibleTB is in decline.
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APPENDIX A. MATHEMATICAL MODEL FOR THE EVOLUTION OF DRUG RESISTANCE
The following system of di¡erence equations, simpli¢ed from Dye & Williams (2000) , describes the dynamics of infection and drug-susceptible pulmonary disease in adults.
Uninfected proportion:
Latent (slow breakdown to disease):
Latent (fast breakdown to disease):
L f ,t ‡ 1ˆLf ,t ‡ cp(I t ‡ P t )S t ‡ cpx(I t ‡ P t )L s,t ¡ (¸f ‡ ·)L f ,t .
(A3)
New infectious:
Non-infectious:
Previously treated, infectious:
Self-cured:
C n,t ‡ 1ˆCn,t ‡ nI t ¡ (r n ‡ ·)C n,t .
Cured (by treatment):
De¢nitions are in table A1. If there are two kinds of pathogen instead of oneödrug resistant as well as drug susceptibleöthey will interact, and the above model needs to be expanded as follows. Drug-resistant cases ¢rst arise through treatment failure. Thus, incidence ratē (1 ¡ µ)(I t ‡ P t ) in equation (A6) is actually the sum of (1 ¡ µ)»(I t ‡ P t ) and¯(1 ¡ µ)(1 ¡ »)(I t ‡ P t ), as shown in equations (1) and (2). Treatment failures carrying resistant strains can transmit to uninfected people in equation (A1), who will be challenged at rate c 0 (I 0 t ‡ P 0 t )S t , as well as at rate c(I t ‡ P t )S t . Moreover, infected individuals in equation (A2) can be reinfected at rate c 0 px(I 0 t ‡ P 0 t )L s,t , from which follows rapid breakdown to disease (equation (A3)). Individuals infected with drug-resistant strains can, reciprocally, be reinfected with drug-susceptible strains. The relative ¢tness of resistant as compared with susceptible strains is represented in this analysis by c'/c, i.e. through di¡erential transmission; the breakdown rates from infection to disease,¸f and¸s, are assumed to be the same for susceptible and resistant strains. The dynamics of non-infectious disease are represented very simply in equation (A5) (e.g. excluding treatment) because our focus here is on transmission and the rate of spread of drug resistance, and not on the total TB burden.
The basic case reproduction number, R 0 , is the number of secondary infectious cases arising from one primary case introduced into a fully susceptible population (Anderson & May 1991) . This quantity is central to our analysis because it determines whether or not drugresistant TB is maintained by a self-sustaining transmission Evolution of antibiotic-resistant TB C. Dye and M. A. Espinal 51 cycle. For a population obeying a system of equations such as (A1)^(A8), R 0ˆb ct, where b is the proportion of infections that leads to infectious cases and t is the average duration of infectiousness, allowing for the e¡ect of chemotherapy. Methods for calculating b and t, both for drug-susceptible and for drug-resistant disease, are discussed by Dye & Williams (2000) .
